TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.

Neslihan CabioğluSemen OnderGizem OnerHüseyin KaratayMustafa TukenmezMahmut MuslumanogluAbdullah İgciYeşim EralpAdnan AydinerPınar SaipEkrem YavuzVahit Ozmen

Published in: BMC cancer (2021)

These findings demonstrate that CTLA-4, PD-1, PDL-1, and TIM-3 were highly expressed in TNBC. Based on these high expression patterns, further studies directed towards combined therapies are warranted in advanced TNBC in future.

Keyphrases

neoadjuvant chemotherapy
locally advanced
poor prognosis
rectal cancer
squamous cell carcinoma
lymph node
sentinel lymph node
radiation therapy
phase ii study
binding protein
long non coding rna
current status
clinical trial
case control
early stage
open label